Glucose Fresenius Kabi (Glucose Monohydrate)

Glucose Fresenius Kabi is used in clinical settings to provide rapid carbohydrate supplementation and to support fluid balance when oral intake is insufficient or contraindicated.

• Treatment of hypoglycemia when intravenous glucose is required.
• Component of parenteral nutrition regimens to supply caloric energy.
• Fluid and electrolyte replacement in perioperative or critical‑care patients.
• Dilution medium for compatible intravenous medications.
• Support for patients with prolonged fasting or malnutrition.
• Maintenance of blood glucose levels during insulin therapy adjustments.

When administered intravenously, glucose solutions can produce a range of physiological responses. Most are mild and transient, while rare events may require medical attention.

Common

• Transient hyperglycemia that resolves with monitoring.
• Mild nausea or vomiting.
• Local irritation or erythema at the infusion site.
• Electrolyte shifts such as mild hypokalemia.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Hypotension from rapid infusion of large volumes.
• Allergic or anaphylactic reactions.
• Metabolic acidosis in patients with impaired metabolism.

Glucose Fresenius Kabi should be administered only after evaluating the patient’s clinical status and laboratory values to avoid complications.

• Verify blood glucose level before infusion to prevent excessive hyperglycemia.
• Adjust infusion rate in patients with renal or cardiac insufficiency.
• Use aseptic technique to maintain sterility of the solution.
• Monitor electrolytes, especially potassium and phosphate, during prolonged therapy.
• Avoid rapid administration of large volumes to reduce risk of circulatory overload.
• Consider compatibility with other IV drugs; incompatibility may cause precipitation.

Glucose solutions can interact with other intravenous agents or affect metabolic pathways, requiring careful coordination with concurrent therapies.

Avoid

• Co‑administration with high‑dose insulin without appropriate glucose monitoring.
• Mixing with calcium‑containing solutions that may precipitate.
• Simultaneous infusion with certain parenteral lipid emulsions that can cause phase separation.

Use with caution

• Concurrent use of diuretics that may exacerbate electrolyte disturbances.
• Administration alongside catecholamines, which can increase glucose production.
• Patients receiving beta‑blockers, as hypoglycemia symptoms may be masked.